We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Dr. Sun, CEO & President
Adjunct Prof. of Beijing Normal University. Executive member of ABO. Dr. Sun received his PhD in biochemistry/cell biology from Tsinghua Univ. in 1989. Dr. Sun was a postdoctoral fellow in Dr. David Barnes’s lab at OSU, working on embryonic stem cells. In 2000, as a co-founder and the President, Dr. Sun started A&G Pharmaceutical in Baltimore with $250K seed fund, created the record of “Generation of mAb in 28 days” for MedImmune and received $2.5 M investment from MedImmune in 2001. In 2006, Dr. Sun started AbMax as a Biotech CRO. Using AbEpiMax, the ONLY B cell-epitope identification program, his team has generated >10,000 antibodies against over 5000 different targets using peptides, many of which have been published in well-known journals such as Nature Medicine. His team has been developing assay kits for immunogenicity and PK studies of antibody drugs. He is also well-known in the filed of de-immunogenicity/humanization of antibodies. His team has been working on development of the next generation of antibody drugs with long-lasting efficacy.
This speaker's sessions: